116 related articles for article (PubMed ID: 38569748)
1. Skeletal muscle mass during chemotherapy for haematological malignancies: a retrospective study.
Takahashi M; Kondo S; Kagawa K; Nakamura M; Maeda Y; Sumitani R; Yagi H; Oura M; Sogabe K; Harada T; Fujii S; Miki H; Endo I; Abe M; Nakamura S
BMJ Support Palliat Care; 2024 May; 14(2):195-199. PubMed ID: 38569748
[TBL] [Abstract][Full Text] [Related]
2. Skeletal Muscle Depletion Predicts the Prognosis of Patients with Advanced Pancreatic Cancer Undergoing Palliative Chemotherapy, Independent of Body Mass Index.
Choi Y; Oh DY; Kim TY; Lee KH; Han SW; Im SA; Kim TY; Bang YJ
PLoS One; 2015; 10(10):e0139749. PubMed ID: 26437072
[TBL] [Abstract][Full Text] [Related]
3. Loss of skeletal muscle mass during palliative chemotherapy is a poor prognostic factor in patients with advanced gastric cancer.
Park SE; Choi JH; Park JY; Kim BJ; Kim JG; Kim JW; Park JM; Chi KC; Hwang IG
Sci Rep; 2020 Oct; 10(1):17683. PubMed ID: 33077864
[TBL] [Abstract][Full Text] [Related]
4. Association between body composition, survival, and toxicity in advanced esophagogastric cancer patients receiving palliative chemotherapy.
Dijksterhuis WPM; Pruijt MJ; van der Woude SO; Klaassen R; Kurk SA; van Oijen MGH; van Laarhoven HWM
J Cachexia Sarcopenia Muscle; 2019 Feb; 10(1):199-206. PubMed ID: 30666831
[TBL] [Abstract][Full Text] [Related]
5. Clinical significance of skeletal muscle density and sarcopenia in patients with pancreatic cancer undergoing first-line chemotherapy: a retrospective observational study.
Kim IH; Choi MH; Lee IS; Hong TH; Lee MA
BMC Cancer; 2021 Jan; 21(1):77. PubMed ID: 33461517
[TBL] [Abstract][Full Text] [Related]
6. Rapidly declining skeletal muscle mass predicts poor prognosis of hepatocellular carcinoma treated with transcatheter intra-arterial therapies.
Kobayashi T; Kawai H; Nakano O; Abe S; Kamimura H; Sakamaki A; Kamimura K; Tsuchiya A; Takamura M; Yamagiwa S; Terai S
BMC Cancer; 2018 Jul; 18(1):756. PubMed ID: 30041616
[TBL] [Abstract][Full Text] [Related]
7. Skeletal Muscle Mass Reduction Velocity as a Simple Prognostic Indicator for Patients with Metastatic Urothelial Carcinoma Receiving Second-Line Chemotherapy.
Nagai T; Naiki T; Iida K; Nozaki S; Etani T; Sugiyama Y; Ando R; Yanase T; Chaya R; Moritoki Y; Kobayashi D; Akita H; Okamura T; Yasui T
Asian Pac J Cancer Prev; 2019 Oct; 20(10):2995-3000. PubMed ID: 31653146
[TBL] [Abstract][Full Text] [Related]
8. Skeletal Muscle Loss during Neoadjuvant Chemotherapy Is an Independent Risk Factor for Postoperative Infectious Complications in Patients with Advanced Esophageal Cancer.
Motoori M; Fujitani K; Sugimura K; Miyata H; Nakatsuka R; Nishizawa Y; Komatsu H; Miyazaki S; Komori T; Kashiwazaki M; Iwase K; Yano M
Oncology; 2018; 95(5):281-287. PubMed ID: 30149394
[TBL] [Abstract][Full Text] [Related]
9. Impact of skeletal muscle mass in patients with unresectable gastric cancer who received palliative first-line chemotherapy based on 5-fluorouracil.
Matsunaga T; Saito H; Miyauchi W; Shishido Y; Miyatani K; Morimoto M; Murakami Y; Hanaki T; Kihara K; Yamamoto M; Tokuyasu N; Takano S; Sakamoto T; Hasegawa T; Fujiwara Y
BMC Cancer; 2021 Nov; 21(1):1219. PubMed ID: 34774016
[TBL] [Abstract][Full Text] [Related]
10. Muscle loss during primary debulking surgery and chemotherapy predicts poor survival in advanced-stage ovarian cancer.
Huang CY; Yang YC; Chen TC; Chen JR; Chen YJ; Wu MH; Jan YT; Chang CL; Lee J
J Cachexia Sarcopenia Muscle; 2020 Apr; 11(2):534-546. PubMed ID: 31999069
[TBL] [Abstract][Full Text] [Related]
11. Association between CT-based body composition assessment and patient outcomes during neoadjuvant chemotherapy for epithelial ovarian cancer.
Wood N; Morton M; Shah SN; Yao M; Barnard H; Tewari S; Suresh A; Kollikonda S; AlHilli MM
Gynecol Oncol; 2023 Feb; 169():55-63. PubMed ID: 36508759
[TBL] [Abstract][Full Text] [Related]
12. Skeletal muscle mass loss and dose-limiting toxicities in metastatic colorectal cancer patients.
Kurk S; Peeters P; Stellato R; Dorresteijn B; de Jong P; Jourdan M; Creemers GJ; Erdkamp F; de Jongh F; Kint P; Simkens L; Tanis B; Tjin-A-Ton M; Van Der Velden A; Punt C; Koopman M; May A
J Cachexia Sarcopenia Muscle; 2019 Aug; 10(4):803-813. PubMed ID: 31094083
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Impact of CT-Quantified Muscle and Fat Distribution before and after First-Line-Chemotherapy in Lung Cancer Patients.
Nattenmüller J; Wochner R; Muley T; Steins M; Hummler S; Teucher B; Wiskemann J; Kauczor HU; Wielpütz MO; Heussel CP
PLoS One; 2017; 12(1):e0169136. PubMed ID: 28107410
[TBL] [Abstract][Full Text] [Related]
14. Loss of skeletal muscle index and survival in patients with metastatic colorectal cancer: Secondary analysis of the phase 3 CAIRO3 trial.
Kurk SA; Peeters PHM; Dorresteijn B; de Jong PA; Jourdan M; Creemers GM; Erdkamp FLG; de Jongh FE; Kint PAM; Poppema BJ; Radema SA; Simkens LHJ; Tanis BC; Tjin-A-Ton MLR; Van Der Velden A; Punt CJA; Koopman M; May AM
Cancer Med; 2020 Feb; 9(3):1033-1043. PubMed ID: 31850687
[TBL] [Abstract][Full Text] [Related]
15. Significance of sarcopenia as a prognostic factor for metastatic urothelial carcinoma patients treated with systemic chemotherapy.
Abe H; Takei K; Uematsu T; Tokura Y; Suzuki I; Sakamoto K; Nishihara D; Yamaguchi Y; Mizuno T; Nukui A; Kobayashi M; Kamai T
Int J Clin Oncol; 2018 Apr; 23(2):338-346. PubMed ID: 29098519
[TBL] [Abstract][Full Text] [Related]
16. Impact of body composition parameters on clinical outcomes in patients with metastatic castrate-resistant prostate cancer treated with docetaxel.
Cushen SJ; Power DG; Murphy KP; McDermott R; Griffin BT; Lim M; Daly L; MacEneaney P; O' Sullivan K; Prado CM; Ryan AM
Clin Nutr ESPEN; 2016 Jun; 13():e39-e45. PubMed ID: 28531567
[TBL] [Abstract][Full Text] [Related]
17. Overall survival and fungal infection-related mortality in patients with invasive fungal infection and neutropenia after myelosuppressive chemotherapy in a tertiary care centre from 1995 to 2006.
Hahn-Ast C; Glasmacher A; Mückter S; Schmitz A; Kraemer A; Marklein G; Brossart P; von Lilienfeld-Toal M
J Antimicrob Chemother; 2010 Apr; 65(4):761-8. PubMed ID: 20106864
[TBL] [Abstract][Full Text] [Related]
18. Assessment of sarcopenia and changes in body composition after neoadjuvant chemotherapy and associations with clinical outcomes in oesophageal cancer.
Yip C; Goh V; Davies A; Gossage J; Mitchell-Hay R; Hynes O; Maisey N; Ross P; Gaya A; Landau DB; Cook GJ; Griffin N; Mason R
Eur Radiol; 2014 May; 24(5):998-1005. PubMed ID: 24535076
[TBL] [Abstract][Full Text] [Related]
19. Assessment of body composition in the advanced stage of castration-resistant prostate cancer: special focus on sarcopenia.
Stangl-Kremser J; Suarez-Ibarrola R; Andrea D; Korn SM; Pones M; Kramer G; Marhold M; Krainer M; Enikeev DV; Glybochko PV; Tamandl D; Shariat SF; Baltzer P
Prostate Cancer Prostatic Dis; 2020 Jun; 23(2):309-315. PubMed ID: 31745255
[TBL] [Abstract][Full Text] [Related]
20. Changes in skeletal muscle and adipose tissue during cytotoxic chemotherapy for testicular germ cell carcinoma and associations with adverse events.
Phuong A; Marquardt JP; O'Malley R; Holt SK; Laidlaw G; Eagle Z; Ngo S; Orcutt D; Schade GR; Lin DW; Schweizer MT; Yezefski T; Yu EY; Montgomery B; Grivas P; Fintelmann FJ; Psutka SP
Urol Oncol; 2022 Oct; 40(10):456.e19-456.e30. PubMed ID: 36028450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]